Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Triebels, V. H.J.M.
Right arrow Articles by van den Bent, M. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Triebels, V. H.J.M.
Right arrow Articles by van den Bent, M. J.
Related Collections
Right arrow All Oncology
Right arrow Primary brain tumor
Right arrow Chemotherapy-tumor
NEUROLOGY 2004;63:904-906
© 2004 American Academy of Neurology
Brief Communications

Salvage PCV chemotherapy for temozolomide-resistant oligodendrogliomas

V. H.J.M. Triebels, MD, M. J.B. Taphoorn, MD, A. A. Brandes, MD, J. Menten, MD, M. Frenay, MD, A. Tosoni, MD, J. M. Kros, MD, E. Biemond-ter Stege, MD, R. H. Enting, MD, A. Allgeier, PhD, I. van Heuvel, RN and M. J. van den Bent, MD

From the Departments of Neuro-Oncology (Drs. Triebels, Biemond-ter Stege, Enting, and van den Bent, and I. van Heuvel) and Pathology (Dr. Kros), Erasmus MC, Dr. Daniel den Hoed Cancer Center, Rotterdam, the Netherlands; Canisius Wilhelmina Hospital (Dr. Triebels), Nijmegen, the Netherlands; University Medical Center Utrecht (Dr. Taphoorn), the Netherlands; Medical Oncology Department (Drs. Brandes and Tosoni), University Hospital Padova, Italy; Department of Radiotherapy-Oncology (Dr. Menten), University Hospital Gasthuisberg, Leuven, Belgium; Centre Antoine Lacassagne (Dr. Frenay), Nice, France; and EORTC DataCenter (Dr. Allgeier), Brussels, Belgium.

Address correspondence and reprint requests to Dr. M.J. van den Bent, Dept Neuro-Oncology, Daniel den Hoed Cancer Center/Erasmus University Hospital Rotterdam, PO Box 5201, 3008AE Rotterdam, the Netherlands; e-mail: m.vandenbent{at}erasmusmc.nl

The authors investigated the results of PCV chemotherapy within a cohort of 24 patients treated within the EORTC study 26971 on temozolomide chemotherapy in recurrent oligodendroglioma. The genotype of the tumors was assessed with fluorescent in situ hybridization with locus specific probes for the region 1p36. Four of the 24 patients responded (17%). Fifty percent of patients were still free from progression at 6 months and 21% were free from progression at 12 months. Although a clear relation existed between loss of 1p and response to temozolomide chemotherapy, this relation was absent in salvage PCV chemotherapy.

Received February 16, 2004. Accepted in final form May 11, 2004.

Presented in part at the 13th European Neurological Society meeting; Istanbul; June 14–18, 2003.

E.B.S. was the recipient of the unrestricted EORTC grant AZ/01/02 from Astra Zeneca.




This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
S. Kesari, D. Schiff, J. Drappatz, D. LaFrankie, L. Doherty, E. A. Macklin, A. Muzikansky, S. Santagata, K. L. Ligon, A. D. Norden, et al.
Phase II Study of Protracted Daily Temozolomide for Low-Grade Gliomas in Adults
Clin. Cancer Res., January 1, 2009; 15(1): 330 - 337.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
D. Schiff, P. D. Brown, and C. Giannini
Outcome in adult low-grade glioma: The impact of prognostic factors and treatment
Neurology, September 25, 2007; 69(13): 1366 - 1373.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
C. Walker, B. Haylock, D. Husband, K. A. Joyce, D. Fildes, M. D. Jenkinson, T. Smith, J. Broome, D. G. du Plessis, and P. C. Warnke
Clinical use of genotype to predict chemosensitivity in oligodendroglial tumors
Neurology, June 13, 2006; 66(11): 1661 - 1667.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
K. A. Jaeckle, K. V. Ballman, R. D. Rao, R. B. Jenkins, and J. C. Buckner
Current Strategies in Treatment of Oligodendroglioma: Evolution of Molecular Signatures of Response
J. Clin. Oncol., March 10, 2006; 24(8): 1246 - 1252.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
R. Stupp, M. E. Hegi, M. J. van den Bent, W. P. Mason, M. Weller, R. O. Mirimanoff, J. G. Cairncross, and on behalf of the European Organisation for Researc
Changing paradigms--an update on the multidisciplinary management of malignant glioma.
Oncologist, February 1, 2006; 11(2): 165 - 180.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2004 by AAN Enterprises, Inc.